Puration Inc Cannabis Beverage Appeal Refreshed with Anheuser Busch and Tilray Deal
December 26 2018 - 1:48PM
via OTC PR WIRE -- Puration, Inc. (USOTC: PURA) (“PURA”) today
reemphasized the company’s cannabis beverage industry experience
and direction in light of the recently announced Anheuser Busch
Inbev NV (NYSE:BUD) and Tilray Inc.
(NASDAQ:TLRY) cannabis-infused beverage deal with both firms
investing $50 million each to research potential beverage
production. “Cannabis infused beverage industry interest heated up
last year around Canada’s legalization of recreational marijuana,”
said Brian Shibley, CEO of Puration. “Among other notable fortune
500 beverage industry announcements regarding interest in the
cannabis beverage market, Puration got its tires kicked by a heavy
weight. Now with the US legalization of hemp farming, big
beverage industry players are renewing their interest. While
the big players invest money to explore potential cannabis infused
beverage industry production, Puration has $1 million in cannabis
infused beverage sales under its belt and has set a goal on ringing
$5 million in sales next year. By the way, we’ve already
experimented with hemp beer. I thought I’d mention that today
in light of the Anheuser Busch announcement.” Puration
recently released a 2018 year-end report detailing the company’s
historical sales and 2019 sales goals. The report also
includes new information on previously announced plans to issue a
dividend of Nouveau Life Pharmaceuticals, (USOTC: NOUV) (“NOUV”)
stock to PURA shareholders that will speed up the issuance in
addition to, management believes, improving the overall value of
the dividend. Management also includes in the update
highlights of business developments with US Cannabis Health
partners NOUV and Kali-Extracts (USOTC: KALY). See the report
on the company’s website at
https://www.purationinc.com/2018-year-end-upate.
To learn more about Puration, Inc., visit
www.purationinc.com.
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the
meaning of the Securities Litigation Reform Act. The statements
reflect the Company's current views with respect to future events
that involve risks and uncertainties. Among others, these risks
include the expectation that any of the companies mentioned herein
will achieve significant sales, the failure to meet schedule or
performance requirements of the companies' contracts, the
companies' liquidity position, the companies' ability to obtain new
contracts, the emergence of competitors with greater financial
resources and the impact of competitive pricing. In the light of
these uncertainties, the forward-looking events referred to in this
release might not occur. These statements have not been evaluated
by the Food and Drug Administration. These products are not
intended to diagnose, treat, cure, or prevent any disease.
Puration, Inc. Brian Shibley,
info@aciconglomerated.com (800) 861-1350
Anheuser Busch Inbev SA NV (NYSE:BUD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anheuser Busch Inbev SA NV (NYSE:BUD)
Historical Stock Chart
From Apr 2023 to Apr 2024